BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 2049932)

  • 1. C1 subcomponent complexes and C2 cleavage in active systemic lupus erythematosus.
    Jonsson H; Sjöholm AG; Mårtensson U; Laurell AB; Sturfelt G
    Complement Inflamm; 1991; 8(1):1-12. PubMed ID: 2049932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C1 subcomponent complexes: basic and clinical aspects.
    Laurell AB; Sjöholm AG
    Behring Inst Mitt; 1993 Dec; (93):292-8. PubMed ID: 8172579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential studies of complement activation in systemic lupus erythematosus.
    Sturfelt G; Johnson U; Sjöholm AG
    Scand J Rheumatol; 1985; 14(2):184-96. PubMed ID: 4001891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C1 dissociation. Spontaneous generation in human serum of a trimer complex containing C1 inactivator, activated C1r, and zymogen C1s.
    Laurell AB; Mårtensson U; Sjöholm AG
    J Immunol; 1987 Dec; 139(12):4145-51. PubMed ID: 2826582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective analysis of C1 dissociation and complement activation in patients with systemic lupus erythematosus.
    Jonsson H; Sturfelt G; Mårtensson U; Truedsson L; Sjöholm AG
    Clin Exp Rheumatol; 1995; 13(5):573-80. PubMed ID: 8575134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-independent activation of C1. II. Evidence for two classes of nonimmune activators of the classical pathway of complement.
    Peitsch MC; Kovacsovics TJ; Tschopp J; Isliker H
    J Immunol; 1987 Mar; 138(6):1871-6. PubMed ID: 3029223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement components, C1 activation and disease activity in SLE.
    Sturfelt G; Sjöholm AG; Svensson B
    Int Arch Allergy Appl Immunol; 1983; 70(1):12-8. PubMed ID: 6293980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trimer and tetramer complexes containing C1 esterase inhibitor, C1r and C1s, in serum and synovial fluid of patients with rheumatic disease.
    Laurell AB; Mårtensson U; Sjöholm AG
    J Immunol Methods; 1990 May; 129(1):55-61. PubMed ID: 2338498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C1 activation and dissociation in disease.
    Laurell AB; Mårtensson U; Sjöholm AG
    Immunol Lett; 1987 Feb; 14(3):249-53. PubMed ID: 3032782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement components, complement activation, and acute phase response in systemic lupus erythematosus.
    Sturfelt G; Sjöholm AG
    Int Arch Allergy Appl Immunol; 1984; 75(1):75-83. PubMed ID: 6086533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoantibodies against Complement Classical Pathway Components C1q, C1r, C1s and C1-Inh in Patients with Lupus Nephritis.
    Radanova M; Vasilev V; Mihaylova G; Kosturkova M; Kishore U; Roumenina L
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human complement subcomponent C1s lacking beta-hydroxyasparagine, sialic acid, and one of its two carbohydrate chains still reassembles with C1q and C1r to form a functional C1 complex.
    Luo C; Thielens NM; Gagnon J; Gal P; Sarvari M; Tseng Y; Tosi M; Zavodszky P; Arlaud GJ; Schumaker VN
    Biochemistry; 1992 May; 31(17):4254-62. PubMed ID: 1533159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of human complement serine-proteinase C1r is down-regulated by a Ca(2+)-dependent intramolecular control that is released in the C1 complex through a signal transmitted by C1q.
    Thielens NM; Illy C; Bally IM; Arlaud GJ
    Biochem J; 1994 Jul; 301 ( Pt 2)(Pt 2):509-16. PubMed ID: 8042996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Classical complement pathway components C1r and C1s: purification from human serum and in recombinant form and functional characterization.
    Rossi V; Bally I; Lacroix M; Arlaud GJ; Thielens NM
    Methods Mol Biol; 2014; 1100():43-60. PubMed ID: 24218249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement activation, circulating C1q binding substances and inflammatory activity in rheumatoid arthritis: relations and changes on suppression of inflammation.
    Berglund K; Laurell AB; Nived O; Sjoholm AG; Sturfelt G
    J Clin Lab Immunol; 1980 Jul; 4(1):7-14. PubMed ID: 7463476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of activation of the classical pathway of complement by Hageman factor fragment.
    Ghebrehiwet B; Randazzo BP; Dunn JT; Silverberg M; Kaplan AP
    J Clin Invest; 1983 May; 71(5):1450-6. PubMed ID: 6304147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surfactant protein A regulates complement activation.
    Watford WT; Wright JR; Hester CG; Jiang H; Frank MM
    J Immunol; 2001 Dec; 167(11):6593-600. PubMed ID: 11714829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating immune complexes and C1 activation in patients with rapidly progressive glomerulonephritis, before and after treatment with immunosuppression and plasma exchange.
    Sjöholm AG; Brun C; Larsen S; Thysell H
    Int Arch Allergy Appl Immunol; 1983; 72(1):9-15. PubMed ID: 6874103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of the first component of human complement (C1) by antibody-antigen aggregates.
    Dodds AW; Sim RB; Porter RR; Kerr MA
    Biochem J; 1978 Nov; 175(2):383-90. PubMed ID: 743203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure of the C1r-C1s interaction of the C1 complex of complement activation.
    Almitairi JOM; Venkatraman Girija U; Furze CM; Simpson-Gray X; Badakshi F; Marshall JE; Schwaeble WJ; Mitchell DA; Moody PCE; Wallis R
    Proc Natl Acad Sci U S A; 2018 Jan; 115(4):768-773. PubMed ID: 29311313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.